RU2019120680A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019120680A3 RU2019120680A3 RU2019120680A RU2019120680A RU2019120680A3 RU 2019120680 A3 RU2019120680 A3 RU 2019120680A3 RU 2019120680 A RU2019120680 A RU 2019120680A RU 2019120680 A RU2019120680 A RU 2019120680A RU 2019120680 A3 RU2019120680 A3 RU 2019120680A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017021542 | 2017-02-08 | ||
JP2017-021542 | 2017-02-08 | ||
PCT/JP2018/004007 WO2018147275A1 (ja) | 2017-02-08 | 2018-02-06 | 腫瘍治療用医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019120680A3 true RU2019120680A3 (ru) | 2021-03-09 |
RU2019120680A RU2019120680A (ru) | 2021-03-09 |
RU2750539C2 RU2750539C2 (ru) | 2021-06-29 |
Family
ID=63107502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019120680A RU2750539C2 (ru) | 2017-02-08 | 2018-02-06 | Фармацевтическая композиция для лечения опухоли |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190388420A1 (ru) |
EP (1) | EP3581183B1 (ru) |
JP (1) | JP6581320B2 (ru) |
KR (1) | KR102539920B1 (ru) |
CN (1) | CN110072528B (ru) |
AU (1) | AU2018219637B2 (ru) |
BR (1) | BR112019014127A2 (ru) |
CA (1) | CA3044658A1 (ru) |
ES (1) | ES2971448T3 (ru) |
IL (1) | IL267159B (ru) |
MX (1) | MX2019006504A (ru) |
RU (1) | RU2750539C2 (ru) |
WO (1) | WO2018147275A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
EP4051278A1 (en) * | 2019-10-29 | 2022-09-07 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
CN117794544A (zh) * | 2021-09-08 | 2024-03-29 | 卫材R&D管理有限公司 | 实体瘤治疗用医药组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
ES2318649T3 (es) | 2000-10-20 | 2009-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Procedimiento de preparacion de derivados de 4-fenoxi quinolinas. |
JPWO2004080462A1 (ja) | 2003-03-10 | 2006-06-08 | エーザイ株式会社 | c−Kitキナーゼ阻害剤 |
JP2005008534A (ja) | 2003-06-17 | 2005-01-13 | Soc De Conseils De Recherches & D'applications Scientifiques (Scras) | 抗癌剤及び癌の治療方法 |
EP1925941B1 (en) | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
CA2723617A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
WO2014208774A1 (en) * | 2013-06-26 | 2014-12-31 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
RU2729936C2 (ru) * | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
WO2016208576A1 (ja) * | 2015-06-23 | 2016-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | (6S,9aS)-N-ベンジル-6-[(4-ヒドロキシフェニル)メチル]-4,7-ジオキソ-8-({6-[3-(ピペラジン-1-イル)アゼチジン-1-イル]ピリジン-2-イル}メチル)-2-(プロプ-2-エン-1-イル)-オクタヒドロ-1H-ピラジノ[2,1-c][1,2,4]トリアジン-1-カルボキサミド化合物の結晶 |
-
2018
- 2018-02-06 ES ES18751614T patent/ES2971448T3/es active Active
- 2018-02-06 EP EP18751614.1A patent/EP3581183B1/en active Active
- 2018-02-06 KR KR1020197016853A patent/KR102539920B1/ko active IP Right Grant
- 2018-02-06 AU AU2018219637A patent/AU2018219637B2/en active Active
- 2018-02-06 RU RU2019120680A patent/RU2750539C2/ru active
- 2018-02-06 JP JP2018567437A patent/JP6581320B2/ja active Active
- 2018-02-06 CN CN201880005026.1A patent/CN110072528B/zh active Active
- 2018-02-06 US US16/465,277 patent/US20190388420A1/en active Granted
- 2018-02-06 CA CA3044658A patent/CA3044658A1/en active Pending
- 2018-02-06 WO PCT/JP2018/004007 patent/WO2018147275A1/ja unknown
- 2018-02-06 MX MX2019006504A patent/MX2019006504A/es unknown
- 2018-02-06 BR BR112019014127-8A patent/BR112019014127A2/pt active Search and Examination
-
2019
- 2019-06-06 IL IL267159A patent/IL267159B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019006504A (es) | 2019-08-14 |
BR112019014127A2 (pt) | 2020-02-11 |
JPWO2018147275A1 (ja) | 2019-11-07 |
ES2971448T3 (es) | 2024-06-05 |
AU2018219637B2 (en) | 2023-07-13 |
AU2018219637A1 (en) | 2019-05-23 |
KR20190110525A (ko) | 2019-09-30 |
EP3581183A1 (en) | 2019-12-18 |
WO2018147275A1 (ja) | 2018-08-16 |
US20190388420A1 (en) | 2019-12-26 |
IL267159A (en) | 2019-10-31 |
CA3044658A1 (en) | 2018-08-16 |
KR102539920B1 (ko) | 2023-06-05 |
EP3581183A4 (en) | 2020-12-09 |
RU2750539C2 (ru) | 2021-06-29 |
JP6581320B2 (ja) | 2019-09-25 |
RU2019120680A (ru) | 2021-03-09 |
IL267159B (en) | 2022-05-01 |
CN110072528B (zh) | 2022-04-26 |
EP3581183B1 (en) | 2023-11-29 |
CN110072528A (zh) | 2019-07-30 |